评估试点生物可用性/生物等价性研究的替代分析方法
Sara Carolina Henriques1,2, João Albuquerque2,3, Paulo Paixão1
1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
试点生物可用性/生物等价性 (BA/BE) 研究受益于替代分析方法. 几何平均值 ƒ2 因子方法提供了更准确的结论测试配方潜力较小的样本大小.
科学领域:
- 药物动力学和制药科学 药物动力学和制药科学
- 药物开发和监管科学 药物开发和监管科学
背景情况:
- 试点生物可用性/生物等价性 (BA/BE) 研究通常使用平均生物等价性,由于样本大小小,对变化敏感.
- 这种敏感性可能会导致关于测试配方潜力的结论不确定.
研究的目的:
- 建议和评估试点BA/BE研究的替代分析方法.
- 为了减少不确定性,并提高从小规模BA/BE试验的结论的可靠性.
主要方法:
- 模拟试点BA/BE交叉研究,使用人口药理动力学建模.
- 与替代方法的平均生物等价性比较:几何最小平方平均比 (GMR),引导分析和算术/几何平均 ƒ2 因子.
- 使用混矩阵评估方法性能.
主要成果:
- 在模拟条件下,几何平均 ƒ2 因子 (Gmean ƒ2) 具有 35 的切线,在测试配方潜力的确定中表现出最高的准确性.
- 与传统方法相比,这种方法可以在较小的样本大小下得出更可靠的结论.
结论:
- Gmean ƒ2因子是分析试点BA/BE研究的一个合适的替代方案.
- 建议建立一个决策树,以指导试点BA/BE试验的样本大小规划和分析方法选择.
更多相关视频
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Bioequivalence: Overview
Bioavailability: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Factors Influencing Bioavailability: First-Pass Elimination
